Interview with Charles Dolladille, MD, author of Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial